Related Experiment Video

Updated: Jun 4, 2026

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
09:28

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

Published on: June 25, 2010

Neonatal screening for metabolic and endocrine disorders

Erik Harms1, Bernhard Olgemöller

  • 1Klinik für Kinder- und Jugendmedizin – Allgemeine Pädiatrie – der Westfä -lischen Wilhelms-Universität Münster. harms@uni-muenster.de

Deutsches Arzteblatt International
|February 3, 2011
PubMed

Insights

Germany expanded neonatal screening in 2005, increasing disease detection by 57%. This enhanced program significantly improves the early identification of treatable inborn errors of metabolism and endocrinopathies in newborns.

Area of Science:

  • Neonatal screening
  • Pediatric endocrinology
  • Inborn errors of metabolism

Background:

  • Neonatal screening is crucial for early detection of treatable endocrinopathies and inborn errors of metabolism.
  • Advancements in diagnosis and treatment necessitate the expansion of existing screening programs.

Purpose of the Study:

  • To evaluate the impact of expanding the German neonatal screening program.
  • To assess the effectiveness of increased screening for metabolic diseases and endocrinopathies.

Main Methods:

  • Selective literature review.
  • Analysis of clinical experience.
  • Evaluation of data from the expanded German neonatal screening program (2005-2008).

Main Results:

  • The German neonatal screening program expanded from 3 to 14 diseases in 2005.
  • Screening from 2005-2008 identified 1932 newborns with treatable conditions out of 2,758,633 screened (prevalence 1:1428).
  • Program expansion led to a 57% increase in overall case detection and a 92% increase for metabolic diseases.

Conclusions:

  • The expanded German neonatal screening program is a more effective preventive measure.
  • The 2005 program enhancement significantly improved the detection rates for critical newborn conditions.
Abstract

More Related Videos

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Biochemical Measurement of Neonatal Hypoxia13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...